LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial

BostonGene and LegoChem Biosciences, Inc. announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers.